LianBio Sponsored ADR LIANY
0.06
0.00
0.00%
as of 25 Sep
- Market cap
- $34.2M
- P/E
- 0.0×
Follow LIANY
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 5.86 | 1.07 | 1.33 | 0.24 | 0.03 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 16.37 | 6.48 | 4.78 | 4.99 | 0.44 |
High Price
|
|||
| — | — | — | — | 87 | 107 | 163 | — | — | — |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | — | — | — |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | 0.00% | 0.00% | 0.00% | — | — | — |
Gross Margin
|
|||
| — | — | — | (24) | (140) | (196) | (111) | 311 | 2 | 5 |
EBT
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | 0 | — | (24) | (140) | (196) | (110) | 311 | 2 | 5 |
Net Income
|
|||
| — | — | — | — | 0 | 1 | 1 | 1 | 1 | — |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | (0.22) | (11.58) | (5.71) | (1.02) | 2.89 | 0.02 | 0.04 |
Earnings/Sh
|
|||
| — | — | — | (0.11) | (8.14) | (4.77) | (0.92) | 2.40 | 0.03 | 0.05 |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.07) | (0.03) | (0.02) | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | (0.11) | (8.22) | (4.79) | (0.94) | 2.40 | 0.03 | 0.05 |
Free CF/Sh
|
|||
| — | — | — | 0.36 | (8.14) | 11.26 | 2.72 | 5.39 | 0.58 | 0.19 |
Book Value/Sh
|
|||
| — | — | — | 108 | 12 | 34 | 108 | 108 | 108 | 109 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | (12) | (98) | (164) | (99) | 259 | 4 | 5 |
Op' Cash Flow
|
|||
| — | — | — | — | (1) | (1) | (2) | 0 | — | — |
Capex
|
|||
| — | — | — | (12) | (99) | (165) | (101) | 259 | 4 | 5 |
FCF
|
|||
| — | — | — | 40 | 271 | 385 | 289 | 577 | 63 | 21 |
Working Cap'
|
|||
| — | — | — | 1 | 2 | 5 | 4 | — | — | — |
Total Debt
|
|||
| — | — | — | (43) | (254) | (383) | (302) | (567) | (52) | (9) |
Net Debt
|
|||
| — | — | — | 39 | (98) | 387 | 294 | 581 | 63 | 21 |
Sh' Equity
|
|||
| — | — | — | (111.09%) | (86.40%) | (55.64%) | (29.56%) | 66.19% | 0.73% | 11.63% |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (2,990.73%) | 0.00% | (450.47%) | (217.43%) | (7.12%) |
ROIC
|
|||
| — | — | — | 32.79% | 245.17% | (135.72%) | (32.39%) | 70.96% | 0.77% | 11.75% |
ROE
|
|||
predictions in italic, sparklines do not include predictions
LianBio Sponsored ADR peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CNTX Context Therapeutics Inc. | $34.1M | 0.0× | Compare |
| ABVC ABVC BioPharma, Inc. | $34.0M | 0.0× | Compare |
| ALGS Aligos Therapeutics, Inc. | $32.6M | 0.0× | Compare |
| MCRB Seres Therapeutics, Inc. | $36.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.4M | — | Compare |
| LBPS 4D pharma PLC Sponsored ADR | $37.2M | 0.0× | Compare |
| BCTX BRIACELL THERAP | $37.2M | 1.9× | Compare |
| ATYR aTyr Pharma, Inc. | $31.4M | 0.0× | Compare |
LianBio Sponsored ADR (LIANY) key facts
- LianBio Sponsored ADR (LIANY) is a Biotechnology company in the Healthcare sector.
- As of September 25, 2026, LIANY traded at $0.06, a market capitalization of $34.2 million.
- Return on equity was 11.8% and debt-to-equity 0.00.
LianBio Sponsored ADR (LIANY) Latest News
21 Mar
11 Stocks that Paid Special Dividends in 2024
11 stocks paid special dividends in 2024, including LianBio (LIANY). LianBio (LIANY) declared a significant special dividend, potentially impacting its future performance.